Sana Biotechnology updates corporate presentation on SC451 and CAR T programs
Sana Biotechnology said its updated corporate presentation outlines progress toward filing an IND for SC451 this year and advances in its in vivo CAR T fusosome programs.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.